Evidence map›Paper›PMID 27366979›Full record

ArticleJAMA oncology2016

Racial/Ethnic Disparities in Genomic Sequencing.

Daniel E Spratt, Tiffany Chan, Levi Waldron, Corey Speers, Felix Y Feng, Olorunseun O Ogunwobi, Joseph R Osborne

Open access · bronzeAbstract read
In one paragraph

Article in JAMA oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 248 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
248citing papers in PubMed, 7 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

248 citing papers in PubMed, 7 syntheses or guidelines pooled it, 354 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Beyond mistrust: Diverse biobanking preferences among parents and adolescents with sickle cell disease.Genetics in medicine : official journal of the American College of Medical Genetics · 2026
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Mutational Landscape ofCurrent issues in molecular biology · 2026
    Article
  14. Review
  15. SOMATIC MUTATION PROFILES IN COLORECTAL CANCERS DIFFER BY POPULATION.medRxiv : the preprint server for health sciences · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

188 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Daniel E SprattDepartment of Radiation Oncology, University of Michigan, Ann Arbor.
Tiffany ChanSchool of Public Health, City University of New York, Hunter College, New York.
Levi WaldronSchool of Public Health, City University of New York, Hunter College, New York.
Corey SpeersDepartment of Radiation Oncology, University of Michigan, Ann Arbor.
Felix Y FengDepartment of Radiation Oncology, University of Michigan, Ann Arbor.
Olorunseun O OgunwobiDepartment of Biological Sciences, City University of New York, Hunter College, New York4Department of Medicine, Cornell University, Weill Cornell Medicine, New York.
Joseph R OsborneDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
University of Michigan–Ann Arbor · USCity University of New York · USHunter College · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2M
Training and Career Development CoreU54CA132378 · NCI · CITY COLLEGE OF NEW YORK · PI Tim Alan Ahles, ADRIANA ESPINOSA · 2008 to 2026
$28.9M
Training and Career Development and Education CoreU54CA137788 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Daniel Alan Heller · 2008 to 2026
$28.1M
Project-002U41HG004059 · NHGRI · ROSWELL PARK CANCER INSTITUTE CORP · PI MORGAN, MARTIN T · 2011 to 2020
$13.2M
Cancer Genomics:Integrative and Scalable Solutions in R / BioconductorU24CA180996 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MORGAN, MARTIN T, WALDRON, LEVI · 2014 to 2023
$6.9M
Immuno-PET With Anti-PSMA 89Zr-J591 mAb For Molecular Imaging of Prostate CancerR21CA153177 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI OSBORNE, JOSEPH REGINALD · 2011 to 2012
$404k
Validation and Clinical Relevance of Ovarian Cancer Molecular SubtypesR03CA191447 · NCI · HUNTER COLLEGE · PI WALDRON, LEVI · 2015 to 2016
$159k
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA046592NCI NIH HHS R03 CA191447NCI NIH HHS R21 CA153177NCI NIH HHS U24 CA180996NCI NIH HHS U54 CA132378NCI NIH HHS U54 CA137788NHGRI NIH HHS U41 HG004059
6 · The paper itself

Abstract

importanceAlthough poorly understood, there is heterogeneity in the molecular biology of cancer across race and ethnicities. The representation of racial minorities in large genomic sequencing efforts is unclear, and could have an impact on health care disparities.

objectiveTo determine the racial distribution among samples sequenced within The Cancer Genome Atlas (TCGA) and the deficit of samples needed to detect moderately common mutational frequencies in racial minorities. DESIGN, SETTING, AND

participantsThis was a retrospective review of individual patient data from TCGA data portal accessed in July 2015. TCGA comprises samples from a wide array of institutions primarily across the United States. Samples from 10 of the 31 currently available tumor types were analyzed, comprising 5729 samples from the approximately 11 000 available. MAIN OUTCOMES AND MEASURES: Using the estimated median somatic mutational frequency, the samples needed beyond TCGA to detect a 10% and 5% mutational frequency over the background somatic mutation frequency were calculated for each tumor type by racial ethnicity.

resultsOf the 5729 samples, 77% (n = 4389) were white, 12% (n = 660) were black, 3% (n = 173) were Asian, 3% (n = 149) were Hispanic, and less than 0.5% combined were from patients of Native Hawaiian, Pacific Islander, Alaskan Native, or American Indian decent. This overrepresents white patients compared with the US population and underrepresents primarily Asian and Hispanic patients. With a somatic mutational frequency of 0.7 (prostate cancer) to 9.9 (lung squamous cell cancer), all tumor types from white patients contained enough samples to detect a 10% mutational frequency. This is in contrast to all other racial ethnicities, for which group-specific mutations with 10% frequency would be detectable only for black patients with breast cancer. Group-specific mutations with 5% frequency would be undetectable in any racial minority, but detectable in white patients for all cancer types except lung (adenocarcinoma and squamous cell carcinoma) and colon cancer. CONCLUSIONS AND RELEVANCE: It is probable, but poorly understood, that ethnic diversity is related to the pathogenesis of cancer, and may have an impact on the generalizability of findings from TCGA to racial minorities. Despite the important benefits that continue to be gained from genomic sequencing, dedicated efforts are needed to avoid widening the already pervasive gap in health care disparities.

Indexed as

EthnicityMutation RateRacial GroupsAlaska NativesAsianBlack or African AmericanDatabases, GeneticGenomicsHealthcare DisparitiesHispanic or LatinoHumansMinority GroupsNative Hawaiian or Pacific IslanderNeoplasmsRetrospective StudiesUnited States

Identifiers

PMID27366979
PMCPMC5123755
OpenAlexW2475362987

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.